During this segment, the panelists explore the results of multiple sclerosis trials that test disease-modifying therapies and conclude that it will take time and more experience ultimately show what the total impact of treating MS is.
 
Patricia K. Coyle, MD, is optimistic that data from emerging trials will provide positive results during the current generation, but believes in order for results to be effective, larger studies will need to be conducted.
 
Leslie Fish, PharmD, believes that in addition to larger studies, there is a need for national guidelines that provide treatment direction to clinicians and eliminate inconsistencies. Dr Fish explains that unlike other diseases, MS does not have a national guideline. There is currently no standard option for treating MS, and there is too much freedom for clinicians to select a therapy option and be the decision maker about the length of time a patient should be treated with therapy.

Episode 9 - Exploring Trials, Data, and the Future of Multiple Sclerosis

During this segment, the panelists discuss the current challenges that need to be addressed to improve the natural history of multiple sclerosis.
Published Online: October 07, 2013
During this segment, the panelists explore the results of multiple sclerosis trials that test disease-modifying therapies and conclude that it will take time and more experience ultimately show what the total impact of treating MS is.
 
Patricia K. Coyle, MD, is optimistic that data from emerging trials will provide positive results during the current generation, but believes in order for results to be effective, larger studies will need to be conducted.
 
Leslie Fish, PharmD, believes that in addition to larger studies, there is a need for national guidelines that provide treatment direction to clinicians and eliminate inconsistencies. Dr Fish explains that unlike other diseases, MS does not have a national guideline. There is currently no standard option for treating MS, and there is too much freedom for clinicians to select a therapy option and be the decision maker about the length of time a patient should be treated with therapy.

View More From This Discussion
Episode 1 Episode 1 - The Changing Tides of Multiple Sclerosis: Where Do We Currently Stand?
Episode 2 Episode 2 - Elucidating the Patient's Starting Point in Care
Episode 3 Episode 3- Exploring the Etiology of Multiple Sclerosis
Episode 4 Episode 4- Characterizing Multiple Sclerosis
Episode 5 Episode 5 - Elucidating the Economic Burden of MS
Episode 6 Episode 6 - Discussing the Pathophysiology of MS
Episode 7 Episode 7 - Increased Monetary Costs of Multiple Sclerosis
Episode 8 Episode 8 - Long-Term Effects of Disease-Modifying Therapies
Episode 9 Episode 9 - Exploring Trials, Data, and the Future of Multiple Sclerosis
Episode 10 Episode 10 - Treatment Complexities
Episode 11 Episode 11 - Clinical Guidelines Vital to the Future of MS
Episode 12 Episode 12 - New MS Agents Challenged
Episode 13 Episode 13 - Treatment Challenges for Progressive Disease
Episode 14 Episode 14 - Concerns about Rising Costs of Treatment
Episode 15 Episode 15 - Controlling Drug Prices and Working at the Population Level
Episode 16 Episode 16 - MRI Scans and MS
Episode 17 Episode 17 - Conclusion: Treatment Advancements and Final Remarks
right-arrow
Related Articles

More on AJMC.COM

$vacMongoViewPlus$